	US 11,771,772 B2
	Glycemic control using intrinsic factor bound to a vitamin B₁₂conjugate of a glucagon-like peptide-1 receptor agonist
Robert Doyle, Manlius, NY (US); Jonathan D. Bortz, St. Louis, MO (US); and David S. Hermelin, St. Louis, MO (US)
Assigned to Syracuse University, Syracuse, NY (US); and Xeragenx LLC, St. Louis, MO (US)
Filed by Syracuse University, Syracuse, NY (US); and Xeragenx LLC, St. Louis, MO (US)
Filed on Apr. 26, 2021, as Appl. No. 17/239,934.
Application 17/239,934 is a division of application No. 15/575,468, abandoned, previously published as PCT/US2016/033426, filed on May 20, 2016.
Claims priority of provisional application 62/169,253, filed on Jun. 1, 2015.
Claims priority of provisional application 62/164,816, filed on May 21, 2015.
Claims priority of provisional application 62/164,048, filed on May 20, 2015.
Prior Publication US 2022/0088203 A1, Mar. 24, 2022
Int. Cl. A61K 47/55 (2017.01); A61K 38/26 (2006.01); A61K 38/17 (2006.01); A61P 3/10 (2006.01); A61K 9/00 (2006.01)

CPC A61K 47/551 (2017.08) [A61K 9/0019 (2013.01); A61K 38/17 (2013.01); A61K 38/26 (2013.01); A61P 3/10 (2018.01)]

12 Claims

1. A method of lowering blood glucose in a subject in need thereof, wherein the method comprises subcutaneously or intraperitoneally administering to the subject an effective amount of a pharmaceutical composition comprising intrinsic factor (IF) complexed with a conjugate comprising B₁₂or an analog thereof conjugated to a peptide comprising a glucagon-like peptide-1 (GLP-1) receptor agonist.